Status:
COMPLETED
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium
Conditions:
Schizophrenia
Psychotic Disorders
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intr...
Detailed Description
Patients with acute schizophrenia are often anxious and uncertain because of the psychotic symptoms they are experiencing. These patients are in need of rapid help and symptom relief. Risperidone, a w...
Eligibility Criteria
Inclusion
- Psychotic patients with schizophrenia who require rapid intervention
- experiencing symptoms of a psychotic disorder
- capable of choosing to be treated
Exclusion
- Patients with a known hypersensitivity to the study drugs
- have participated in an investigational drug trial within 30 days of study initiation
- known to be unresponsive to treatment with risperidone or the comparator drug
- known to have benzodiazepine dependence (addiction to this class of anti-anxiety drugs)
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2003
Estimated Enrollment :
226 Patients enrolled
Trial Details
Trial ID
NCT00249171
Start Date
June 1 2001
End Date
February 1 2003
Last Update
January 14 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.